Finished
Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer
NCT02048150 · City of Hope Medical Center · Updated 22 Oct 2026
- What is being tested
- anti-PSMA monoclonal antibody MDX1201-A488; robot-assisted laparoscopic surgery; diffuse optical imaging; pharmacological study; Laboratory Biomarker; Questionnaire
- For
- Adenocarcinoma of the Prostate; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
- Kind of study
- Tests a treatment or device on volunteers. Phase 1.
- Who can join
- Ages 36 years to 74 years. About 7 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 5 Oct 2015, ends 1 Feb 2023. Registered 29 Jan 2014.
- Results
- None posted yet.
In the researchers' words
This pilot clinical trial studies the best dose of anti-prostate specific membrane antigen (PSMA) monoclonal antibody MDX1201-A488 (MDX1201-A488) given before surgery to aid in visualization of the prostate. Attaching a fluorescence, a substance that emits radiation that is visible, to the anti-PMSA antibody and injecting it into the body may help identify the tumor when specialized microscopes are used.
Sites
- City of Hope Medical CenterDuarte, California, United States